Form 4: TransMedics Director Receives RSU Grant

Director Edward M. Basile acquired 2,922 restricted stock units in TransMedics Group, Inc. as part of a routine equity grant.

Summary

• Director Edward M. Basile was granted 2,922 restricted stock units (RSUs) on May 20, 2026.
• Each RSU represents a contingent right to receive one share of TransMedics Group, Inc. common stock.
• Following this transaction, the director's total beneficial ownership of common stock increased to 5,788 shares.
• The transaction was executed pursuant to a Rule 10b5-1(c) trading plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Standard market risks associated with equity ownership in the medical technology sector.

Future Outlook

Not applicable as this is a routine insider transaction filing.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices designed to incentivize long-term performance and align director interests with those of the shareholders.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation practices for mid-cap medical technology companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact; reflects standard director compensation structure.

Next Steps

• Vesting of the granted restricted stock units according to the company's equity incentive plan.

Key Dates

Keywords

TransMedics, TMDX, Form 4, Insider Trading, Director Compensation, Restricted Stock Units